Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
POMALYST - official hemodialysis and indication check
Product / population
POMALYST - official hemodialysis and indication check; selected renal passages, not a complete prescribing monograph.
Renal method
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source revision
Prescribing information revised February 2025.
Retrieved
2026-09-09
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
POMALYST: indication, cycle days and HD timing remain linked
The dialysis dose differs between multiple myeloma and Kaposi sarcoma. The renal change does not remove the treatment-free portion of the 28-day cycle.
What to reconcile: Confirm indication, days on treatment and post-HD administration; do not turn the modified dose into uninterrupted daily treatment.
DailyMed / Celgene Corporation · POMALYST - official hemodialysis and indication check; selected renal passages, not a complete prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Source date: Prescribing information revised February 2025. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The official label confirms distinct dialysis reductions: 3 mg daily for multiple myeloma and 4 mg daily for Kaposi sarcoma. Both retain days 1-21 of 28-day cycles. On hemodialysis days, give the dose after dialysis. This confirmation addresses selected renal instructions, not complete protocol validation; independent review of the full regimen remains pending.
Identity check: DailyMed labeler Celgene Corporation. Current archive version 26 published 2025-05-12. This archive date is separate from the prescribing-information revision and does not itself prove that renal instructions changed. Raw SPL XML was not independently downloaded or hashed.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.